{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:53Z","timestamp":1791327353677,"version":"4.3.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a disabling neurological disorder that greatly impacts quality of life and productivity. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have recently improved preventive migraine therapy. However, some patients show limited efficacy, loss of response, or adverse effects, prompting interest in switching between mAbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this work is to evaluate the effectiveness of switching between mAbs in chronic migraine\/high-frequency episodic migraine (CM\/HFEM) patients and to identify potential clinical predictors of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre, real-life, prospective study was conducted in a tertiary hospital headache unit which includes patients with CM or HFEM who switched from one mAb to another without a treatment gap greater than 1\u202fmonth. Monthly headache days (MHDs), monthly migraine days (MMDs), monthly analgesic consumption (MAC), and medication overuse (MO) were recorded 3\u202fmonths before and at three and 6\u202fmonths after switching. Subanalyses were performed based on the mechanism of action (anti-ligand vs. anti-receptor), reason for switch (lack or loss of efficacy), and clinical predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-five patients (52.2\u202f\u00b1\u202f9.6\u202fyears; 87.1% female; 95.3% CM) were included. At 3\u202fmonths post-switch, reductions were observed in MHDs (\u22125.8\u202fdays,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), MMDs (\u22125.8\u202fdays,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), MAC (\u22125.6\u202fdays,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), and MO (\u221222.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). At 6\u202fmonths, these improvements persisted. A\u202f\u2265\u202f50% response was achieved in 29.4% (25\/85) of patients at month 3 and 32.9% (28\/85) at month 6. One-third of patients whose switch included a change in mechanism of action responded, while none of those who underwent anti-ligand to anti-ligand switch showed a reduction of MHDs &amp;gt;50%. Both patients with loss and lack of efficacy to the first mAb improved significantly, though early response was more frequent among those with prior loss of efficacy. Obesity and concomitant tension-type headache were associated with poorer early response, while migraine with aura predicted better late response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching between mAbs could be an effective strategy for some CM and HFEM patients who fail initial mAb therapy, rescuing approximately one-third of non-responders. The therapeutic benefit seems to be greater when the second antibody targets a different mechanism of action. These real-world findings support the use of individualized switching strategies in refractory migraine management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1799960","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:23:05Z","timestamp":1773638585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching strategies with CGRP monoclonal antibodies: an observational study in a headache clinic"],"prefix":"10.3389","volume":"17","author":[{"given":"Marcos","family":"Polanco","sequence":"first","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Gonz\u00e1lez-Quintanilla","sequence":"additional","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Madera","sequence":"additional","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"P\u00e9rez-Pereda","sequence":"additional","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"G\u00e1rate","sequence":"additional","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[{"name":"Service of Neurology, University Hospital Marqu\u00e9s de Valdecilla, Universidad de Cantabria and IDIVAL","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the global burden of disease study 2023","volume":"24","year":"2025","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-024-01740-3","article-title":"Societal and economic burden of migraine in Spain: results from the 2020 National Health and wellness survey","volume":"25","author":"Garc\u00eda-Azor\u00edn","year":"2024","journal-title":"J Headache Pain"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for migraine prevention 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-823357-3.00024-0","article-title":"CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention","volume":"199","author":"Caronna","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2023-333295","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/head.14865","article-title":"Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: a retrospective cohort study","volume":"65","author":"Jaimes","year":"2025","journal-title":"Headache"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000518899","article-title":"Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series","volume":"85","author":"Patier Ruiz","year":"2022","journal-title":"Eur Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3331024231160519","DOI":"10.1177\/03331024231160519","article-title":"Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study","volume":"43","author":"Iannone","year":"2023","journal-title":"Cephalalgia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","article-title":"Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study","volume":"14","author":"Overeem","year":"2023","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-024-01790-7","article-title":"Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies: insights from the German NeuroTransData registry","volume":"25","author":"Hong","year":"2024","journal-title":"J Headache Pain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","article-title":"Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine","volume":"23","author":"Driessen","year":"2022","journal-title":"J Headache Pain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"120811","DOI":"10.1016\/j.jns.2023.120811","article-title":"Switching between anticalcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing","volume":"453","author":"Ihara","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-023-01593-2","article-title":"Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study","volume":"24","author":"Straube","year":"2023","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/ejhpharm-2023-003779","article-title":"Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab","volume":"32","author":"Talbot","year":"2025","journal-title":"Eur J Hosp Pharm"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"A154","DOI":"10.1136\/ejhpharm-2023-eahp.321","article-title":"Switching between anti-calcitonin gene-related peptide monoclonal antibodies in migraine. In: abstracts of the 27th EAHP congress, Lisbon, Portugal, 22\u201324 March 2023","volume":"30","author":"Ribera Puig","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","article-title":"Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review","volume":"65","author":"Romozzi","year":"2025","journal-title":"Headache"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","article-title":"A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response","volume":"16","author":"Hong","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17512433.2024.2417655","article-title":"Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists","volume":"17","author":"Waliszewska-Pros\u00f3\u0142","year":"2024","journal-title":"Expert Rev Clin Pharmacol"}],"updated-by":[{"DOI":"10.3389\/fneur.2026.1845315","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1799960\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:53:37Z","timestamp":1776351217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1799960\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":21,"alternative-id":["10.3389\/fneur.2026.1799960"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1799960","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1799960"}}